Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.

Franco Capsoni, Piercarlo Sarzi-Puttini, Fabiola Atzeni, Francesca Minonzio, Paola Bonara, Andrea Doria, Mario Carrabba

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Neutrophils are known to be targets for the biological activity of tumour necrosis factor (TNF)-alpha in the pathogenesis of rheumatoid arthritis (RA). Therefore, these cells may be among the targets of anti-TNF-alpha therapy. In this study we evaluated the effect of therapy with adalimumab (a fully human anti-TNF-alpha mAb; dosage: 40 mg subcutaneously every other week) on certain phenotypic and functional aspects of neutrophils obtained from 10 selected patients with RA and 20 healthy control individuals. Peripheral blood neutrophils were obtained at baseline and during anti-TNF-alpha therapy (2, 6 and 12 weeks after the first administration of adalimumab). All patients had been receiving a stable regimen of hydroxychloroquine, methotrexate and prednisone for at least 3 months before and during the study. Baseline neutrophil chemotaxis was significantly decreased in RA patients when compared with control individuals (P <0.001). Two weeks after the first administration of adalimumab, chemotactic activity was completely restored, with no differences noted between patients and control individuals; these normal values were confirmed 6 and 12 weeks after the start of anti-TNF-alpha therapy. Phagocytic activity and CD11b membrane expression on neutrophils were similar between RA patients and control individuals; no modifications were observed during TNF-alpha neutralization. The production of reactive oxygen species, both in resting and PMA (phorbol 12-myristate 13-acetate)-stimulated cells, was significantly higher in RA patients at baseline (P <0.05) and was unmodified by anti-TNF-alpha mAb. Finally, we showed that the activation antigen CD69, which was absent on control neutrophils, was significantly expressed on neutrophils from RA patients at baseline (P <0.001, versus control individuals); however, the molecule was barely detectable on cells obtained from RA patients during adalimumab therapy. Because CD69 potentially plays a role in the pathogenesis of arthritis, our findings suggest that neutrophils are among the targets of anti-TNF-alpha activity in RA and may provide an insight into a new and interesting mechanism of action of anti-TNF-alpha mAbs in the control of inflammatory arthritis.

Original languageEnglish
JournalArthritis Research and Therapy
Volume7
Issue number2
Publication statusPublished - 2005

Fingerprint

Rheumatoid Arthritis
Neutrophils
Tumor Necrosis Factor-alpha
Arthritis
Hydroxychloroquine
Therapeutics
Adalimumab
Chemotaxis
Prednisone
Methotrexate
Reactive Oxygen Species
Reference Values
Acetates
Membranes

Cite this

Capsoni, F., Sarzi-Puttini, P., Atzeni, F., Minonzio, F., Bonara, P., Doria, A., & Carrabba, M. (2005). Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. Arthritis Research and Therapy, 7(2).

Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. / Capsoni, Franco; Sarzi-Puttini, Piercarlo; Atzeni, Fabiola; Minonzio, Francesca; Bonara, Paola; Doria, Andrea; Carrabba, Mario.

In: Arthritis Research and Therapy, Vol. 7, No. 2, 2005.

Research output: Contribution to journalArticle

Capsoni, F, Sarzi-Puttini, P, Atzeni, F, Minonzio, F, Bonara, P, Doria, A & Carrabba, M 2005, 'Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.', Arthritis Research and Therapy, vol. 7, no. 2.
Capsoni F, Sarzi-Puttini P, Atzeni F, Minonzio F, Bonara P, Doria A et al. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. Arthritis Research and Therapy. 2005;7(2).
Capsoni, Franco ; Sarzi-Puttini, Piercarlo ; Atzeni, Fabiola ; Minonzio, Francesca ; Bonara, Paola ; Doria, Andrea ; Carrabba, Mario. / Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. In: Arthritis Research and Therapy. 2005 ; Vol. 7, No. 2.
@article{331939eb2ca144a5baa10190a5343bd9,
title = "Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.",
abstract = "Neutrophils are known to be targets for the biological activity of tumour necrosis factor (TNF)-alpha in the pathogenesis of rheumatoid arthritis (RA). Therefore, these cells may be among the targets of anti-TNF-alpha therapy. In this study we evaluated the effect of therapy with adalimumab (a fully human anti-TNF-alpha mAb; dosage: 40 mg subcutaneously every other week) on certain phenotypic and functional aspects of neutrophils obtained from 10 selected patients with RA and 20 healthy control individuals. Peripheral blood neutrophils were obtained at baseline and during anti-TNF-alpha therapy (2, 6 and 12 weeks after the first administration of adalimumab). All patients had been receiving a stable regimen of hydroxychloroquine, methotrexate and prednisone for at least 3 months before and during the study. Baseline neutrophil chemotaxis was significantly decreased in RA patients when compared with control individuals (P <0.001). Two weeks after the first administration of adalimumab, chemotactic activity was completely restored, with no differences noted between patients and control individuals; these normal values were confirmed 6 and 12 weeks after the start of anti-TNF-alpha therapy. Phagocytic activity and CD11b membrane expression on neutrophils were similar between RA patients and control individuals; no modifications were observed during TNF-alpha neutralization. The production of reactive oxygen species, both in resting and PMA (phorbol 12-myristate 13-acetate)-stimulated cells, was significantly higher in RA patients at baseline (P <0.05) and was unmodified by anti-TNF-alpha mAb. Finally, we showed that the activation antigen CD69, which was absent on control neutrophils, was significantly expressed on neutrophils from RA patients at baseline (P <0.001, versus control individuals); however, the molecule was barely detectable on cells obtained from RA patients during adalimumab therapy. Because CD69 potentially plays a role in the pathogenesis of arthritis, our findings suggest that neutrophils are among the targets of anti-TNF-alpha activity in RA and may provide an insight into a new and interesting mechanism of action of anti-TNF-alpha mAbs in the control of inflammatory arthritis.",
author = "Franco Capsoni and Piercarlo Sarzi-Puttini and Fabiola Atzeni and Francesca Minonzio and Paola Bonara and Andrea Doria and Mario Carrabba",
year = "2005",
language = "English",
volume = "7",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "2",

}

TY - JOUR

T1 - Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.

AU - Capsoni, Franco

AU - Sarzi-Puttini, Piercarlo

AU - Atzeni, Fabiola

AU - Minonzio, Francesca

AU - Bonara, Paola

AU - Doria, Andrea

AU - Carrabba, Mario

PY - 2005

Y1 - 2005

N2 - Neutrophils are known to be targets for the biological activity of tumour necrosis factor (TNF)-alpha in the pathogenesis of rheumatoid arthritis (RA). Therefore, these cells may be among the targets of anti-TNF-alpha therapy. In this study we evaluated the effect of therapy with adalimumab (a fully human anti-TNF-alpha mAb; dosage: 40 mg subcutaneously every other week) on certain phenotypic and functional aspects of neutrophils obtained from 10 selected patients with RA and 20 healthy control individuals. Peripheral blood neutrophils were obtained at baseline and during anti-TNF-alpha therapy (2, 6 and 12 weeks after the first administration of adalimumab). All patients had been receiving a stable regimen of hydroxychloroquine, methotrexate and prednisone for at least 3 months before and during the study. Baseline neutrophil chemotaxis was significantly decreased in RA patients when compared with control individuals (P <0.001). Two weeks after the first administration of adalimumab, chemotactic activity was completely restored, with no differences noted between patients and control individuals; these normal values were confirmed 6 and 12 weeks after the start of anti-TNF-alpha therapy. Phagocytic activity and CD11b membrane expression on neutrophils were similar between RA patients and control individuals; no modifications were observed during TNF-alpha neutralization. The production of reactive oxygen species, both in resting and PMA (phorbol 12-myristate 13-acetate)-stimulated cells, was significantly higher in RA patients at baseline (P <0.05) and was unmodified by anti-TNF-alpha mAb. Finally, we showed that the activation antigen CD69, which was absent on control neutrophils, was significantly expressed on neutrophils from RA patients at baseline (P <0.001, versus control individuals); however, the molecule was barely detectable on cells obtained from RA patients during adalimumab therapy. Because CD69 potentially plays a role in the pathogenesis of arthritis, our findings suggest that neutrophils are among the targets of anti-TNF-alpha activity in RA and may provide an insight into a new and interesting mechanism of action of anti-TNF-alpha mAbs in the control of inflammatory arthritis.

AB - Neutrophils are known to be targets for the biological activity of tumour necrosis factor (TNF)-alpha in the pathogenesis of rheumatoid arthritis (RA). Therefore, these cells may be among the targets of anti-TNF-alpha therapy. In this study we evaluated the effect of therapy with adalimumab (a fully human anti-TNF-alpha mAb; dosage: 40 mg subcutaneously every other week) on certain phenotypic and functional aspects of neutrophils obtained from 10 selected patients with RA and 20 healthy control individuals. Peripheral blood neutrophils were obtained at baseline and during anti-TNF-alpha therapy (2, 6 and 12 weeks after the first administration of adalimumab). All patients had been receiving a stable regimen of hydroxychloroquine, methotrexate and prednisone for at least 3 months before and during the study. Baseline neutrophil chemotaxis was significantly decreased in RA patients when compared with control individuals (P <0.001). Two weeks after the first administration of adalimumab, chemotactic activity was completely restored, with no differences noted between patients and control individuals; these normal values were confirmed 6 and 12 weeks after the start of anti-TNF-alpha therapy. Phagocytic activity and CD11b membrane expression on neutrophils were similar between RA patients and control individuals; no modifications were observed during TNF-alpha neutralization. The production of reactive oxygen species, both in resting and PMA (phorbol 12-myristate 13-acetate)-stimulated cells, was significantly higher in RA patients at baseline (P <0.05) and was unmodified by anti-TNF-alpha mAb. Finally, we showed that the activation antigen CD69, which was absent on control neutrophils, was significantly expressed on neutrophils from RA patients at baseline (P <0.001, versus control individuals); however, the molecule was barely detectable on cells obtained from RA patients during adalimumab therapy. Because CD69 potentially plays a role in the pathogenesis of arthritis, our findings suggest that neutrophils are among the targets of anti-TNF-alpha activity in RA and may provide an insight into a new and interesting mechanism of action of anti-TNF-alpha mAbs in the control of inflammatory arthritis.

UR - http://www.scopus.com/inward/record.url?scp=25144464372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144464372&partnerID=8YFLogxK

M3 - Article

C2 - 15743471

AN - SCOPUS:25144464372

VL - 7

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 2

ER -